We’ve had a number of questions recently about Mounjaro, the new weight loss injection (tirzepatide). Here is the latest information for patients registered at Barlow Medical Centre.
Mounjaro is not yet available at Barlow Medical Centre
You may have seen recent news about tirzepatide being made available through the NHS to support people living with obesity. While this is a positive development, the treatment is not yet available in GP surgeries, including here at Barlow.
Locally, NHS Greater Manchester is working to introduce this treatment through a specialist-led service, but it is not expected to launch until Autumn 2025 at the earliest.
What this means for our patients
We kindly ask that you do not contact the practice about Mounjaro at this time, as we are currently unable to assess eligibility or issue prescriptions.
When the service does become available, it will only be offered to those who meet strict national eligibility criteria, including:
- A Body Mass Index (BMI) of 40 or above
- Or 37.5 and above for those from Black, Asian, or other minority ethnic backgrounds
- Plus at least four of the following health conditions:
- Type 2 Diabetes
- High Blood Pressure (Hypertension)
- Heart Disease
- Obstructive Sleep Apnoea
- Abnormal Cholesterol Levels (Dyslipidaemia)
What happens next?
Initially, Mounjaro will only be prescribed via specialist hospital clinics. We do not yet know if or when it might be made available through general practice.
We will update this page as soon as we receive further information from NHS Greater Manchester.
Thank you for your understanding and for helping us keep our phone lines and online systems available for those who need immediate clinical support.